BACKGROUND AND PURPOSE: Spleen tyrosine kinase (SYK) has broad biological functions in inflammation and immunity. The orally administered SYK inhibitor BI 894416 was investigated in a single-rising-dose Phase I study in healthy volunteers and in a combined single- and multiple-rising-dose Phase Ib study in patients with mild asthma. EXPERIMENTAL APPROACH: The single-blinded, partially randomised, placebo-controlled Phase I study evaluated single doses of BI 894416 (3-70 mg) in healthy volunteers. The single-blinded, randomised, placebo-controlled Phase Ib study in patients with mild asthma evaluated three single doses (75-170 mg) and four multiple doses (10-60 mg) of BI 894416 over an interval of 9 days. The primary objective of both studies was safety and tolerability, assessing the proportion of participants with drug-related adverse events (AEs). Secondary endpoints related to pharmacokinetics and efficacy (Phase Ib study only). KEY RESULTS: All except one randomised participant completed treatment (56 healthy volunteers and 68 mild asthmatics [29 received a single dose and 39 received multiple doses]). The most frequent drug-related AEs were headache, diarrhoea and nausea (all of mild/moderate intensity). No serious AEs occurred. BI 894416 was rapidly absorbed with median time-to-peak concentration 0.5-1.0 h; exposure increased in a dose-dependent manner. Basophils and nasal epithelial cells showed dose-dependent modulation of activation- and disease-associated genes and pathways. CONCLUSION AND IMPLICATIONS: BI 894416 was safe and well tolerated in healthy volunteers and mild asthmatics. Results from target engagement biomarkers demonstrated treatment- and dose-dependent cellular modulation, potentially leading to decreased airway inflammation and airway obstruction.
Keywords
